226 related articles for article (PubMed ID: 18724386)
1. Endogenous and synthetic agonists of GPR119 differ in signalling pathways and their effects on insulin secretion in MIN6c4 insulinoma cells.
Ning Y; O'Neill K; Lan H; Pang L; Shan LX; Hawes BE; Hedrick JA
Br J Pharmacol; 2008 Dec; 155(7):1056-65. PubMed ID: 18724386
[TBL] [Abstract][Full Text] [Related]
2. Stimulating beta cell replication and improving islet graft function by GPR119 agonists.
Gao J; Tian L; Weng G; Bhagroo NV; Sorenson RL; O'Brien TD; Luo J; Guo Z
Transpl Int; 2011 Nov; 24(11):1124-34. PubMed ID: 21902730
[TBL] [Abstract][Full Text] [Related]
3. Activation of GPR119 by fatty acid agonists augments insulin release from clonal β-cells and isolated pancreatic islets and improves glucose tolerance in mice.
Moran BM; Abdel-Wahab YH; Flatt PR; McKillop AM
Biol Chem; 2014 Apr; 395(4):453-64. PubMed ID: 24323890
[TBL] [Abstract][Full Text] [Related]
4. GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell.
Lauffer LM; Iakoubov R; Brubaker PL
Diabetes; 2009 May; 58(5):1058-66. PubMed ID: 19208912
[TBL] [Abstract][Full Text] [Related]
5. The cytoprotective effects of oleoylethanolamide in insulin-secreting cells do not require activation of GPR119.
Stone VM; Dhayal S; Smith DM; Lenaghan C; Brocklehurst KJ; Morgan NG
Br J Pharmacol; 2012 Apr; 165(8):2758-70. PubMed ID: 22029844
[TBL] [Abstract][Full Text] [Related]
6. Structural basis for constitutive activity and agonist-induced activation of the enteroendocrine fat sensor GPR119.
Engelstoft MS; Norn C; Hauge M; Holliday ND; Elster L; Lehmann J; Jones RM; Frimurer TM; Schwartz TW
Br J Pharmacol; 2014 Dec; 171(24):5774-89. PubMed ID: 25117266
[TBL] [Abstract][Full Text] [Related]
7. Agonists at GPR119 mediate secretion of GLP-1 from mouse enteroendocrine cells through glucose-independent pathways.
Lan H; Lin HV; Wang CF; Wright MJ; Xu S; Kang L; Juhl K; Hedrick JA; Kowalski TJ
Br J Pharmacol; 2012 Apr; 165(8):2799-807. PubMed ID: 22029751
[TBL] [Abstract][Full Text] [Related]
8. GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis.
Lan H; Vassileva G; Corona A; Liu L; Baker H; Golovko A; Abbondanzo SJ; Hu W; Yang S; Ning Y; Del Vecchio RA; Poulet F; Laverty M; Gustafson EL; Hedrick JA; Kowalski TJ
J Endocrinol; 2009 May; 201(2):219-30. PubMed ID: 19282326
[TBL] [Abstract][Full Text] [Related]
9. DS-8500a, an Orally Available G Protein-Coupled Receptor 119 Agonist, Upregulates Glucagon-Like Peptide-1 and Enhances Glucose-Dependent Insulin Secretion and Improves Glucose Homeostasis in Type 2 Diabetic Rats.
Matsumoto K; Yoshitomi T; Ishimoto Y; Tanaka N; Takahashi K; Watanabe A; Chiba K
J Pharmacol Exp Ther; 2018 Dec; 367(3):509-517. PubMed ID: 30217957
[TBL] [Abstract][Full Text] [Related]
10. Biased signaling of lipids and allosteric actions of synthetic molecules for GPR119.
Hassing HA; Fares S; Larsen O; Pad H; Hauge M; Jones RM; Schwartz TW; Hansen HS; Rosenkilde MM
Biochem Pharmacol; 2016 Nov; 119():66-75. PubMed ID: 27569424
[TBL] [Abstract][Full Text] [Related]
11. Oleoyl-lysophosphatidylinositol enhances glucagon-like peptide-1 secretion from enteroendocrine L-cells through GPR119.
Arifin SA; Paternoster S; Carlessi R; Casari I; Ekberg JH; Maffucci T; Newsholme P; Rosenkilde MM; Falasca M
Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Sep; 1863(9):1132-1141. PubMed ID: 29883799
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the insulin releasing and antihyperglycaemic activities of GPR55 lipid agonists using clonal beta-cells, isolated pancreatic islets and mice.
McKillop AM; Moran BM; Abdel-Wahab YH; Flatt PR
Br J Pharmacol; 2013 Nov; 170(5):978-90. PubMed ID: 23992544
[TBL] [Abstract][Full Text] [Related]
13. Bidirectional GPR119 Agonism Requires Peptide YY and Glucose for Activity in Mouse and Human Colon Mucosa.
Tough IR; Forbes S; Herzog H; Jones RM; Schwartz TW; Cox HM
Endocrinology; 2018 Apr; 159(4):1704-1717. PubMed ID: 29471473
[TBL] [Abstract][Full Text] [Related]
14. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
[TBL] [Abstract][Full Text] [Related]
15. 5-Hydroxy-eicosapentaenoic acid is an endogenous GPR119 agonist and enhances glucose-dependent insulin secretion.
Kogure R; Toyama K; Hiyamuta S; Kojima I; Takeda S
Biochem Biophys Res Commun; 2011 Dec; 416(1-2):58-63. PubMed ID: 22079287
[TBL] [Abstract][Full Text] [Related]
16. GPR119 Agonist AS1269574 Activates TRPA1 Cation Channels to Stimulate GLP-1 Secretion.
Chepurny OG; Holz GG; Roe MW; Leech CA
Mol Endocrinol; 2016 Jun; 30(6):614-29. PubMed ID: 27082897
[TBL] [Abstract][Full Text] [Related]
17. 2-OMe-lysophosphatidylcholine analogues are GPR119 ligands and activate insulin secretion from βTC-3 pancreatic cells: Evaluation of structure-dependent biological activity.
Drzazga A; Sowińska A; Krzemińska A; Okruszek A; Paneth P; Koziołkiewicz M; Gendaszewska-Darmach E
Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Jan; 1863(1):91-103. PubMed ID: 29079451
[TBL] [Abstract][Full Text] [Related]
18. A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release.
Chu ZL; Jones RM; He H; Carroll C; Gutierrez V; Lucman A; Moloney M; Gao H; Mondala H; Bagnol D; Unett D; Liang Y; Demarest K; Semple G; Behan DP; Leonard J
Endocrinology; 2007 Jun; 148(6):2601-9. PubMed ID: 17289847
[TBL] [Abstract][Full Text] [Related]
19. N-oleoyldopamine enhances glucose homeostasis through the activation of GPR119.
Chu ZL; Carroll C; Chen R; Alfonso J; Gutierrez V; He H; Lucman A; Xing C; Sebring K; Zhou J; Wagner B; Unett D; Jones RM; Behan DP; Leonard J
Mol Endocrinol; 2010 Jan; 24(1):161-70. PubMed ID: 19901198
[TBL] [Abstract][Full Text] [Related]
20. Lysophosphatidylcholine and its phosphorothioate analogues potentiate insulin secretion via GPR40 (FFAR1), GPR55 and GPR119 receptors in a different manner.
Drzazga A; Kristinsson H; Sałaga M; Zatorski H; Koziołkiewicz M; Gendaszewska-Darmach E; Bergsten P
Mol Cell Endocrinol; 2018 Sep; 472():117-125. PubMed ID: 29225068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
